536 related articles for article (PubMed ID: 23169517)
1. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
[TBL] [Abstract][Full Text] [Related]
2. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
[TBL] [Abstract][Full Text] [Related]
4. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
[TBL] [Abstract][Full Text] [Related]
5. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
Lee RJ; Saylor PJ; Michaelson MD; Rothenberg SM; Smas ME; Miyamoto DT; Gurski CA; Xie W; Maheswaran S; Haber DA; Goldin JG; Smith MR
Clin Cancer Res; 2013 Jun; 19(11):3088-94. PubMed ID: 23553848
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
Vergote IB; Smith DC; Berger R; Kurzrock R; Vogelzang NJ; Sella A; Wheler J; Lee Y; Foster PG; Weitzman R; Buckanovich RJ
Eur J Cancer; 2017 Sep; 83():229-236. PubMed ID: 28755607
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Daud A; Kluger HM; Kurzrock R; Schimmoller F; Weitzman AL; Samuel TA; Moussa AH; Gordon MS; Shapiro GI
Br J Cancer; 2017 Feb; 116(4):432-440. PubMed ID: 28103611
[TBL] [Abstract][Full Text] [Related]
10. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.
Smith DC; Daignault-Newton S; Grivas P; Reichert ZR; Hussain M; Cooney KA; Caram M; Alva A; Jacobson J; Yablon C; Mehra R; Escara-Wilke J; Shelley G; Keller ET
Clin Genitourin Cancer; 2020 Aug; 18(4):332-339.e2. PubMed ID: 32299729
[TBL] [Abstract][Full Text] [Related]
12. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
[TBL] [Abstract][Full Text] [Related]
13. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Hellerstedt BA; Vogelzang NJ; Kluger HM; Yasenchak CA; Aftab DT; Ramies DA; Gordon MS; Lara P
Clin Lung Cancer; 2019 Mar; 20(2):74-81.e1. PubMed ID: 30528315
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
Cabanillas ME; Brose MS; Holland J; Ferguson KC; Sherman SI
Thyroid; 2014 Oct; 24(10):1508-14. PubMed ID: 25102375
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.
Corn PG; Zhang M; Nogueras-Gonzalez GM; Xiao L; Zurita AJ; Subudhi SK; Tu SM; Aparicio AM; Coarfa C; Rajapakshe K; Huang S; Navone NM; Lin SH; Wang G; Ramachandran S; Titus MA; Panaretakis T; Gallick GE; Efstathiou E; Troncoso P; Logothetis C
Clin Cancer Res; 2020 Mar; 26(5):990-999. PubMed ID: 31941830
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Escudier B; Powles T; Motzer RJ; Olencki T; Arén Frontera O; Oudard S; Rolland F; Tomczak P; Castellano D; Appleman LJ; Drabkin H; Vaena D; Milwee S; Youkstetter J; Lougheed JC; Bracarda S; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):765-772. PubMed ID: 29309249
[TBL] [Abstract][Full Text] [Related]
17. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
[TBL] [Abstract][Full Text] [Related]
18. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM
J Transl Med; 2016 Jan; 14():12. PubMed ID: 26762579
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
20. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
